Trial Profile

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2024 Results of pre-specified analysis evaluating efficacy and safety of dapagliflozin according to baseline age and sex, published in the Journal of General Internal Medicine
20 Jan 2023 Results of a pre-specified analysis assessing benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease published in the Diabetes Care
06 Dec 2022 Results of post hoc analysis, evaluating the effects of dapagliflozin on first hospitalizations and all (first and subsequent) hospitalizations and to explore effects on cause-specific hospitalizations, published in the Annals of Internal Medicine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com